Two hurdles to jump for SkyePharma, as it changes CEO
On the same day that UK-based SkyePharma (LSE: SKP) announced that Axel Mueller has resigned as chief executive and as a director of the company, with immediate effect to pursue other interests, analysts at Edison Investment Research issued a report on SkyePharma noting hurdles ahead for the company.
Peter Grant, chief financial officer since November 2006, has been appointed chief executive. Mr Grant will retain responsibility for the group’s financial matters and will oversee the continuing activities to achieve Flutiform, a fixed-dose combination (FDC) of formoterol, a long-acting bronchodilator, regulatory approval.
Edison analysts said SkyePharma’s newly-appointed CEO, the former finance chief Peter Grant, should be well placed to negotiate the refinancing of the group’s £83 million ($130.1 million) of convertible bonds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze